Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Bugworks
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Study of BWC0977 Safety, Tolerability, & PK/PD in Healthy Adults
Details : BWC0977 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Communicable Diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2025
Lead Product(s) : BWC0977
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Bugworks
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Terevalefim
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Angion Biomedica
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Terevalefim
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Angion Biomedica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANX009
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Annexon Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 02, 2020
Lead Product(s) : ANX009
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Annexon Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BOS-356
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 19, 2016
Lead Product(s) : BOS-356
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etelcalcetide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 02, 2010
Lead Product(s) : Etelcalcetide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
